Showing results (151-160 of 187) with videos related to
Sort By:
Pageof 19
Scientific Reports|January 8, 2025
Regulation of fibronectin and collagens type I, III and VI by TNF-α, TGF-β, IL-13, and tofacitinibFrederik S Gillesberg, Martin Pehrsson, Anne-Christine Bay-Jensen, et al.Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|March 4, 2017
Ischemic Stroke Mortality Is More Strongly Associated with Anemia on Admission Than with Underweight StatusSatoshi Kubo, Naohisa Hosomi, Naoyuki Hara, et al.Journal of Pharmaceutical Sciences|June 14, 2022
Preclinical Characterization of ASP2713, a Novel Igβ and FcγRIIB Cross-Linking Antibody, for Prediction of Human Pharmacokinetics and Clinically Effective DoseKentaro Konishi, Koji Nakamura, Yuichi Hanada, et al.Rheumatology (Oxford, England)|November 7, 2023
Safety and efficacy of anifrolumab therapy in systemic lupus erythematosus in real-world clinical practice: LOOPS registryYusuke Miyazaki, Masashi Funada, Shingo Nakayamada, et al.Rheumatology (Oxford, England)|March 14, 2022
Nailfold microvascular abnormalities are associated with a higher prevalence of pulmonary arterial hypertension in patients with MCTDYasuyuki Todoroki, Satoshi Kubo, Kazuhisa Nakano, et al.RMD Open|January 22, 2025
Switching to biological DMARDs versus cycling among JAK inhibitors in patients with rheumatoid arthritis and with inadequate response to JAK inhibitors: from FIRST registryYusuke Miyazaki, Shingo Nakayamada, Hiroaki Tanaka, et al.Modern Rheumatology|September 8, 2011
Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study)Tsutomu Takeuchi, Yoshiya Tanaka, Yuko Kaneko, et al.Annals of the Rheumatic Diseases|October 30, 2023
Extracting immunological and clinical heterogeneity across autoimmune rheumatic diseases by cohort-wide immunophenotypingHiroaki Tanaka, Yukinori Okada, Shingo Nakayamada, et al.International Immunopharmacology|November 15, 2021
Discovery of a novel Igβ and FcγRIIB cross-linking antibody, ASP2713, and its potential application in the treatment of systemic lupus erythematosusYukihiro Kitanaga, Daisuke Yamajuku, Satoshi Kubo, et al.International Journal of Rheumatic Diseases|February 6, 2020
The additive effects of hydroxychloroquine to maintenance therapy with standard of care in patients with systemic lupus erythematosusIppei Miyagawa, Kazuhisa Nakano, Shingo Nakayamada, et al.Pageof 19